Kirill Dmitriev, Director General of the Russian Direct Investment Fund (RDIF), and Veronika Skvortsova, Head of the Federal Medical and Biological Agency (FMBA of Russia), signed an agreement on strategic cooperation and joint work on promising investment projects related to the supply of medicines and medical devices. According to the press service of the RDIF, investment projects will ensure the development and improvement of the competitiveness of Russian products and the economy as a whole.
“The FMBA of Russia and its subordinate structures have a number of innovative developments that strengthen Russia’s medicinal sovereignty and have a high export potential. Thanks to a wide network of international partners and expertise, including that accumulated during the COVID-19 pandemic, the RDIF will play a leading role in promoting the FMBA of Russia’s original developments and products abroad. In particular, the allergy vaccine developed by the SRC Institute of Immunology of the FMBA of Russia has a great potential for entering the international market. RDIF and FMBA will focus on its joint promotion in Russia and globally,” the message says.
In addition, one of the first projects within the framework of cooperation between the parties will be the launch of full-cycle production of conjugated vaccines at the facilities of the St. Petersburg Research Institute of Vaccines and Serums of the FMBA of Russia with the involvement of investments of RDIF and partners, which will ensure import substitution in the country.
“RDIF and FMBA of Russia will jointly develop world-class biopharmaceutical developments and promote the availability of modern innovative medicine in Russia and abroad, in cooperation with the World Health Organization. The FMBA of Russia will provide support for the transfer of drug production technologies subject to a positive assessment of the commercial attractiveness of such projects by the RDIF,” the press service added.
